fbpx
01 / 05
Was COVID Also an Inequality Pandemic?

Blog Post | Income & Inequality

Was COVID Also an Inequality Pandemic?

COVID slowed but couldn’t stop the fall in global inequality.

Summary: Recent debates have framed global inequality as rapidly worsening, particularly in response to the COVID-19 pandemic. Evidence from the Inequality of Human Progress Index indicates that, despite temporary setbacks, long-term declines in inequality across multiple dimensions of wellbeing have largely persisted, with global disparities remaining well below 1990s levels.


Affordability fears, talk of a “K-shaped” economy, and claims of a new Gilded Age have pushed inequality to the center of today’s policy debates. Calls for a worldwide wealth tax and other unprecedented measures are not treated as radical but as inevitable—across academianon-profitsthe press, and international organizations, including the United Nations.

The COVID-19 pandemic seemed to clinch the case. As economies contracted and progress in poorer countries stalled, it was easy to assume that decades of convergence between developed and developing countries had come to an end. The authors of one Oxfam paper, for example, proclaimed during the pandemic that “unparalleled action [is] needed to combat unprecedented inequality in the wake of COVID-19.”

New research suggests a more nuanced reality. The updated Inequality of Human Progress Index assesses how the pandemic affected progress toward a more prosperous and equal world.

The pandemic clearly slowed improvement in global living standards and interrupted the pace at which countries were becoming more equal. It did not, however, cancel out the long-term, positive trends. Even under the strain of COVID-19, its attendant lockdowns, and other forceful policy responses, global inequality across key measures of well-being remained lower than it was a generation ago.

The index looks beyond income alone. It measures inequality across eight dimensions that shape everyday life, including lifespan, child survival, nutrition, education, internet access, environmental safety, income, and political freedom. The index, which I co-authored with George Mason University economist Vincent Geloso, seeks to offer a fuller view of gaps in global development, taking into account more aspects of human well-being than any prior index of inequality.

The data show a substantial decline in global inequality over the past three decades as rising prosperity allowed poor countries to narrow gaps with rich ones. That pattern held through 2019. During the pandemic years of 2020 and 2021, progress slowed sharply and, in some areas, stalled or modestly reversed. Yet the earlier gains were not erased.

This distinction is important. COVID-19 was a severe shock. Life expectancy fell worldwide. School closures disrupted education. Economic activity and international trade declined, with especially devastating effects on low-income countries. The index reflects these setbacks. Inequality stopped falling at its earlier pace and, in some measures, edged upward slightly after years of progress. Still, the overall level of global inequality remained far below where it stood in the 1990s.

In a few areas, improvement continued even during the crisis. Internet access expanded rapidly, especially in poorer countries, reducing inequality in access to information to its lowest level on record. Faster regulatory approvals amid the pandemic helped bring more people online. In Kenya, for example, Alphabet’s high-altitude internet balloons were finally cleared in 2020, allowing rural areas to gain internet access for the first time. The project had been stalled in regulatory review for nearly two years before the crisis prompted action.

Not all the data were encouraging. Inequality in political liberty ticked up during the pandemic as many countries took a turn toward greater authoritarianism. Even with the long-term shift toward electoral democracy intact, the setback shows the importance of protecting political liberty during emergencies.

For all the turmoil, the damage across different measures of well-being was thankfully limited.

These findings complicate popular claims that the world is experiencing a runaway increase in inequality. Calls for a global wealth tax, massive new aid commitments, or other significant expansions of state redistribution often rest on the premise that trade and free enterprise have failed to deliver shared gains. The data suggest otherwise.

If anything, the pandemic highlighted how sensitive progress can be to disruptions in markets. Countries with greater economic freedom generally proved more resilient. In contrast, prolonged lockdowns and restrictions often imposed heavy costs on poorer populations, particularly in countries where remote work and online schooling were not viable options for most people.

The broader lesson is that global convergence is neither automatic nor guaranteed, but instead depends on certain conditions such as undisturbed markets, even as long-term progress has proven more robust than critics often assume.

Mistaken narratives about global inequality have real consequences. They shape public opinion and influence policymakers to embrace sweeping interventions. A more accurate assessment of recent history suggests a need for caution.

COVID-19 tested the global economy in ways few events in modern history have. It slowed human progress and exposed vulnerabilities. At the same time, it demonstrated the durability of the long-term trend toward lower global inequality. Preserving and strengthening the policies and institutions that made that progress possible, including economic and political freedoms, remains a better bet than assuming they have already failed. The gains of recent decades have left the world both better off and more equal.

This article was published in the Orange County Register on 2/1/2026.

Nigerian Tribune | Communicable Disease

Nigeria Nears Trachoma Elimination

“Nigeria is close to eliminating trachoma as a public health problem, with only 11 Local Government Areas (LGAs) left to achieve elimination, the Director of the National Trachoma Programme at the Federal Ministry of Health and Social Welfare, Nicholas Olobio, has said.

Olobio disclosed this on Thursday in Abuja during a learning event organised by Sightsavers to review progress under the AcceleraTE Trachoma Elimination Programme, which has supported Nigeria’s trachoma response since 2018.

He said Nigeria had made significant progress towards eliminating the blinding disease, revealing that mass drug administration (MDA) had been stopped in 116 LGAs, representing about 87 per cent of the country’s elimination target.”

From Nigerian Tribune.

Reuters | Accidents, Injuries & Poisonings

US Traffic Deaths Fell Sharply in Early 2026

“U.S. traffic deaths fell to the lowest rate since 2014 in the first ​three months of the year after a sharp rise ‌in road fatalities during the COVID pandemic.

The National Highway Traffic Safety Administration said on Wednesday traffic deaths had dropped 4.3% to 7,770 in the three-month period ending March 31, the ​lowest number since 2015. The fatality rate fell to 0.99 ​fatalities per 100 million vehicle miles traveled, the lowest ⁠quarterly figure since 2014.”

From Reuters.

UCL | Noncommunicable Disease

Trial Shows Safer Antibiotic Option for Staph Blood Infection

“The SNAP trial, funded in the UK by the National Institute for Health and Care Research (NIHR) found that a little used antibiotic, cefazolin, is as effective as and safer than the current UK standard therapy, flucloxacillin, for treating life-threatening staph blood infections. More than half of staph blood infections lead to sepsis and 15% to 25% of those who get these infections die within three months.

The researchers also found that a commonly used antibiotic, penicillin, can be used when the staph is treatable with this in the laboratory. And that similarly this is probably as effective as flucloxacillin, and safer.

The findings from the SNAP trial, published in the New England Journal of Medicine (NEJM) and The Lancet, challenge the long-held assumption that flucloxacillin should remain the default treatment and provide important new evidence to guide treatment strategy.”

From UCL.